The Q2 beat and guidance raise, especially the first organic revenue growth since 2023 and the highest DSA book-to-bill in nearly four years, suggest a cyclical recovery in drug development outsourcing. The company's Investor Day on September 24, 2026 will provide further strategic detail. Traders should watch for continued order momentum and margin expansion as the divested businesses are behind the company.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 5 $260.72entry
- T+1 · 3mo ago +1.84%α +2.00% · $265.51
- T+5 · 3mo ago +9.07%α +8.72% · $284.37
- T+20 · 3mo ago +11.91%α +12.51% · $291.76
- T+60 · 19d ago +44.25%α +44.31% · $376.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Charles River Laboratories reported Q2 2026 revenue of $1.00B (down 2.7% reported / +0.1% organic YoY) and non-GAAP EPS of $3.02, beating consensus estimates of $2.73 by 10.6%. The company raised its full-year organic revenue guidance to 0.0%-1.0% (from -1.5% to -0.5%) and its non-GAAP EPS guidance to $11.15-$11.45, driven by improving demand in DSA and better-than-expected Manufacturing performance. This marks the first quarter of organic revenue growth since Q3 2023 and signals a potential inflection in underlying demand trends.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue $1.00B vs consensus $977.2M; organic revenue grew 0.1% YoY (first positive since Q3 2023)
- Non-GAAP EPS $3.02 beats consensus of $2.73 by 10.6% (down 3.2% from $3.12 a year ago)
- Raised 2026 organic revenue guidance to 0.0%-1.0% from (1.5%)-(0.5%) and non-GAAP EPS to $11.15-$11.45 from $10.80-$11.30
- GAAP net loss of $(0.03)/share driven by $63.7M loss on CDMO & Cell Solutions divestiture completed in May 2026
- Non-GAAP operating margin 20.5% improved 420 bps sequentially from Q1 2026 (16.3%) but down 160 bps YoY
- Repurchased $100M of common stock in Q2 at avg price $174; $700M remaining under $1.0B authorization
- DSA segment achieved highest net book-to-bill in nearly four years, indicating strengthening demand
- Completed divestitures of CDMO, Cell Solutions, and certain European Discovery Services sites in May 2026
Financial Impact
Non-GAAP EPS beat of $0.29 vs consensus ($3.02 vs $2.73) and full-year guidance raised by $0.25 at midpoint; revenue beat of $27M vs consensus
Risk Factors
- RMS organic revenue declined 1.4% YoY, and non-GAAP operating margin contracted in all three segments
- Non-GAAP EPS guidance increase partly offset by higher tax rate and deferred comp investment gains that may not recur
- Guidance assumes successful execution of restructuring and efficiency initiatives; any delays could pressure margins
- GAAP earnings remain deeply negative due to divestiture-related charges; underlying cash flow metrics warrant monitoring
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001100682-26-000115 |
| Document: crl-20260805.htm | 0001100682-26-000115 |
| Document: 0001100682-26-000115-index-headers.html | 0001100682-26-000115 |
| Document: 0001100682-26-000115-index.html | 0001100682-26-000115 |
| Document: 0001100682-26-000115.txt | 0001100682-26-000115 |
| 8-K Data (Synthetic) | 0001100682-26-000115 |
Track record
17 reports on CRL
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $333.18 Now $335.52 +0.70% settles Dec 15
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $345.80 Now $335.52 −2.97% settles Dec 9
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $353.34 Now $335.52 −5.04% settles Dec 8
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $313.02 Now $335.52 +7.19% settles Dec 4
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $326.29 Now $335.52 +2.83% settles Dec 3
- Oct 26, 202621d ago Insider Cluster Neutral 2/10 Entry $358.84 Now $335.52 −6.50% settles Nov 24
- Oct 22, 202625d ago 144 Neutral 2/10 Entry $345.37 Now $335.52 −2.85% settles Nov 20
- Oct 21, 202626d ago Institutional Cluster Bullish 4/10 Entry $339.66 Now $335.52 −1.22% settles Nov 19
- Sep 24, 20267w ago 8-K Bullish 6/10 Entry $294.44 to $339.66 Now $335.52 +13.95% ▲ +15.36% +15.78% vs SPY
- Aug 27, 202611w ago Insider Cluster Neutral 3/10 Entry $291.50 to $294.59 Now $335.52 +15.10% ▲ +1.06% +1.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers